Logo image of EMR.CA

EMERGENT METALS CORP (EMR.CA) Stock Fundamental Analysis

TSX-V:EMR - TSX Venture Exchange - CA29103R1055 - Common Stock - Currency: CAD

0.03  0 (0%)

Fundamental Rating

1

EMR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 794 industry peers in the Metals & Mining industry. The financial health of EMR is average, but there are quite some concerns on its profitability. EMR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EMR has reported negative net income.
EMR had a negative operating cash flow in the past year.
In the past 5 years EMR always reported negative net income.
EMR had a negative operating cash flow in each of the past 5 years.
EMR.CA Yearly Net Income VS EBIT VS OCF VS FCFEMR.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M

1.2 Ratios

EMR has a Return On Assets of -26.51%. This is comparable to the rest of the industry: EMR outperforms 45.21% of its industry peers.
Looking at the Return On Equity, with a value of -90.61%, EMR is doing worse than 65.11% of the companies in the same industry.
Industry RankSector Rank
ROA -26.51%
ROE -90.61%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EMR.CA Yearly ROA, ROE, ROICEMR.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

EMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EMR.CA Yearly Profit, Operating, Gross MarginsEMR.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

There is no outstanding debt for EMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EMR.CA Yearly Shares OutstandingEMR.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
EMR.CA Yearly Total Debt VS Total AssetsEMR.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -27.25, we must say that EMR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -27.25, EMR is not doing good in the industry: 77.83% of the companies in the same industry are doing better.
There is no outstanding debt for EMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.25
ROIC/WACCN/A
WACCN/A
EMR.CA Yearly LT Debt VS Equity VS FCFEMR.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M -2M

2.3 Liquidity

A Current Ratio of 0.10 indicates that EMR may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.10, EMR is doing worse than 81.86% of the companies in the same industry.
EMR has a Quick Ratio of 0.10. This is a bad value and indicates that EMR is not financially healthy enough and could expect problems in meeting its short term obligations.
EMR's Quick ratio of 0.10 is on the low side compared to the rest of the industry. EMR is outperformed by 81.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
EMR.CA Yearly Current Assets VS Current LiabilitesEMR.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

EMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.21%, which is quite impressive.
EPS 1Y (TTM)44.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-377.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EMR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EMR.CA Price Earnings VS Forward Price EarningsEMR.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EMR.CA Per share dataEMR.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0.01 0.02 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EMR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EMERGENT METALS CORP

TSX-V:EMR (7/21/2025, 7:00:00 PM)

0.03

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A N/A
Earnings (Next)08-27 2025-08-27
Inst Owners5.6%
Inst Owner ChangeN/A
Ins Owners2.52%
Ins Owner ChangeN/A
Market Cap1.55M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.51%
ROE -90.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 580.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z -27.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)886.9%
Cap/Depr(5y)967.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-377.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.81%
OCF growth 3YN/A
OCF growth 5YN/A